Altman Peter 4

What Happened Peter Altman, President, CEO and a Director of BioCardia, bought 5,100 shares of BioCardia, Inc. (BCDA) in an open-market purchase on May 15, 2026. The reported weighted-average price was $1.02 per share, for a total reported purchase value of $5,202. This is an outright purchase (a bullish-type transaction in that the insider acquired shares rather than sold them).

Key Details

• Transaction type: Purchase (Code P) — open market or private purchase
• Transaction date: 2026-05-15; Filing date / Period of Report: 2026-05-15 (filed same day)
• Price: weighted-average $1.02 per share; trades ranged from $1.01 to $1.03 (see footnote)
• Shares acquired: 5,100; Total value reported: $5,202
• Shares owned after transaction: Not specified in the provided filing excerpt
• Footnote: The price is a weighted average of multiple trades ($1.01–$1.03). The reporting person offers to provide a breakdown of shares purchased at each price upon request (Footnote F1)
• No 10b5-1 plan, option exercise, tax withholding, gift, or other special arrangement was disclosed in the provided details
• Filing timeliness: Not late (transaction and filing date match)

Context Insider purchases can be of interest to retail investors because they show executives putting personal money into the company; however, this purchase is relatively small in dollar terms ($~5.2k). There is no additional disclosure here about total holdings or a trading plan, so this single purchase should be viewed as one data point rather than a definitive signal.